Cargando…

Iterative Structure-Based Peptide-Like Inhibitor Design against the Botulinum Neurotoxin Serotype A

The botulinum neurotoxin serotype A light chain (BoNT/A LC) protease is the catalytic component responsible for the neuroparalysis that is characteristic of the disease state botulism. Three related peptide-like molecules (PLMs) were designed using previous information from co-crystal structures, sy...

Descripción completa

Detalles Bibliográficos
Autores principales: Zuniga, Jorge E., Hammill, Jared T., Drory, Omri, Nuss, Jonathan E., Burnett, James C., Gussio, Rick, Wipf, Peter, Bavari, Sina, Brunger, Axel T.
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2894858/
https://www.ncbi.nlm.nih.gov/pubmed/20614028
http://dx.doi.org/10.1371/journal.pone.0011378
_version_ 1782183228596027392
author Zuniga, Jorge E.
Hammill, Jared T.
Drory, Omri
Nuss, Jonathan E.
Burnett, James C.
Gussio, Rick
Wipf, Peter
Bavari, Sina
Brunger, Axel T.
author_facet Zuniga, Jorge E.
Hammill, Jared T.
Drory, Omri
Nuss, Jonathan E.
Burnett, James C.
Gussio, Rick
Wipf, Peter
Bavari, Sina
Brunger, Axel T.
author_sort Zuniga, Jorge E.
collection PubMed
description The botulinum neurotoxin serotype A light chain (BoNT/A LC) protease is the catalytic component responsible for the neuroparalysis that is characteristic of the disease state botulism. Three related peptide-like molecules (PLMs) were designed using previous information from co-crystal structures, synthesized, and assayed for in vitro inhibition against BoNT/A LC. Our results indicate these PLMS are competitive inhibitors of the BoNT/A LC protease and their K(i) values are in the nM-range. A co-crystal structure for one of these inhibitors was determined and reveals that the PLM, in accord with the goals of our design strategy, simultaneously involves both ionic interactions via its P1 residue and hydrophobic contacts by means of an aromatic group in the P2′ position. The PLM adopts a helical conformation similar to previously determined co-crystal structures of PLMs, although there are also major differences to these other structures such as contacts with specific BoNT/A LC residues. Our structure further demonstrates the remarkable plasticity of the substrate binding cleft of the BoNT/A LC protease and provides a paradigm for iterative structure-based design and development of BoNT/A LC inhibitors.
format Text
id pubmed-2894858
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-28948582010-07-07 Iterative Structure-Based Peptide-Like Inhibitor Design against the Botulinum Neurotoxin Serotype A Zuniga, Jorge E. Hammill, Jared T. Drory, Omri Nuss, Jonathan E. Burnett, James C. Gussio, Rick Wipf, Peter Bavari, Sina Brunger, Axel T. PLoS One Research Article The botulinum neurotoxin serotype A light chain (BoNT/A LC) protease is the catalytic component responsible for the neuroparalysis that is characteristic of the disease state botulism. Three related peptide-like molecules (PLMs) were designed using previous information from co-crystal structures, synthesized, and assayed for in vitro inhibition against BoNT/A LC. Our results indicate these PLMS are competitive inhibitors of the BoNT/A LC protease and their K(i) values are in the nM-range. A co-crystal structure for one of these inhibitors was determined and reveals that the PLM, in accord with the goals of our design strategy, simultaneously involves both ionic interactions via its P1 residue and hydrophobic contacts by means of an aromatic group in the P2′ position. The PLM adopts a helical conformation similar to previously determined co-crystal structures of PLMs, although there are also major differences to these other structures such as contacts with specific BoNT/A LC residues. Our structure further demonstrates the remarkable plasticity of the substrate binding cleft of the BoNT/A LC protease and provides a paradigm for iterative structure-based design and development of BoNT/A LC inhibitors. Public Library of Science 2010-06-30 /pmc/articles/PMC2894858/ /pubmed/20614028 http://dx.doi.org/10.1371/journal.pone.0011378 Text en Zuniga et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Zuniga, Jorge E.
Hammill, Jared T.
Drory, Omri
Nuss, Jonathan E.
Burnett, James C.
Gussio, Rick
Wipf, Peter
Bavari, Sina
Brunger, Axel T.
Iterative Structure-Based Peptide-Like Inhibitor Design against the Botulinum Neurotoxin Serotype A
title Iterative Structure-Based Peptide-Like Inhibitor Design against the Botulinum Neurotoxin Serotype A
title_full Iterative Structure-Based Peptide-Like Inhibitor Design against the Botulinum Neurotoxin Serotype A
title_fullStr Iterative Structure-Based Peptide-Like Inhibitor Design against the Botulinum Neurotoxin Serotype A
title_full_unstemmed Iterative Structure-Based Peptide-Like Inhibitor Design against the Botulinum Neurotoxin Serotype A
title_short Iterative Structure-Based Peptide-Like Inhibitor Design against the Botulinum Neurotoxin Serotype A
title_sort iterative structure-based peptide-like inhibitor design against the botulinum neurotoxin serotype a
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2894858/
https://www.ncbi.nlm.nih.gov/pubmed/20614028
http://dx.doi.org/10.1371/journal.pone.0011378
work_keys_str_mv AT zunigajorgee iterativestructurebasedpeptidelikeinhibitordesignagainstthebotulinumneurotoxinserotypea
AT hammilljaredt iterativestructurebasedpeptidelikeinhibitordesignagainstthebotulinumneurotoxinserotypea
AT droryomri iterativestructurebasedpeptidelikeinhibitordesignagainstthebotulinumneurotoxinserotypea
AT nussjonathane iterativestructurebasedpeptidelikeinhibitordesignagainstthebotulinumneurotoxinserotypea
AT burnettjamesc iterativestructurebasedpeptidelikeinhibitordesignagainstthebotulinumneurotoxinserotypea
AT gussiorick iterativestructurebasedpeptidelikeinhibitordesignagainstthebotulinumneurotoxinserotypea
AT wipfpeter iterativestructurebasedpeptidelikeinhibitordesignagainstthebotulinumneurotoxinserotypea
AT bavarisina iterativestructurebasedpeptidelikeinhibitordesignagainstthebotulinumneurotoxinserotypea
AT brungeraxelt iterativestructurebasedpeptidelikeinhibitordesignagainstthebotulinumneurotoxinserotypea